The global Immunosuppressant for Systemic Lupus Erythematosus market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Immunosuppressant for Systemic Lupus Erythematosus is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Immunosuppressant for Systemic Lupus Erythematosus is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Immunosuppressant for Systemic Lupus Erythematosus in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Immunosuppressant for Systemic Lupus Erythematosus include Alcon, Alkem Laboratories, Allergan, Amneal Pharmaceuticals, Astellas Pharma, Baxter, Beijing Jialin Pharmaceutical, Genentech and Jubilant Cadista, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Immunosuppressant for Systemic Lupus Erythematosus, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immunosuppressant for Systemic Lupus Erythematosus.
Report Scope
The Immunosuppressant for Systemic Lupus Erythematosus market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immunosuppressant for Systemic Lupus Erythematosus market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immunosuppressant for Systemic Lupus Erythematosus companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Alcon
Alkem Laboratories
Allergan
Amneal Pharmaceuticals
Astellas Pharma
Baxter
Beijing Jialin Pharmaceutical
Genentech
Jubilant Cadista
LGM Pharma
LingNan Pharmaceutical
Merck
Mimetogen Pharmaceuticals
Mylan
Otsuka Pharmaceutical
Par Pharmaceutical
Pfizer
Powerdone
Regenerx Biopharmaceuticals
Roxane Laboratories
Sandoz
Sanofi
Santen Pharmaceutical
Takeda
Sine
Strides Pharma
Talon Therapeutics
Teva
United Biotech
West Ward Pharmaceuticals
Segment by Type
Cyclophosphamide
Mycophenolate Mofetil
Azathioprine
Cyclosporine A
Tacrolimus
Methotrexate
Leflunomide
Vincristine
Others
Segment by Application
Hospital
Clinic
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immunosuppressant for Systemic Lupus Erythematosus companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cyclophosphamide
1.2.3 Mycophenolate Mofetil
1.2.4 Azathioprine
1.2.5 Cyclosporine A
1.2.6 Tacrolimus
1.2.7 Methotrexate
1.2.8 Leflunomide
1.2.9 Vincristine
1.2.10 Others
1.3 麻豆原创 by Application
1.3.1 Global Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Pharmacy
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Perspective (2019-2030)
2.2 Immunosuppressant for Systemic Lupus Erythematosus Growth Trends by Region
2.2.1 Global Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Immunosuppressant for Systemic Lupus Erythematosus Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Immunosuppressant for Systemic Lupus Erythematosus Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Dynamics
2.3.1 Immunosuppressant for Systemic Lupus Erythematosus Industry Trends
2.3.2 Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Drivers
2.3.3 Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Challenges
2.3.4 Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immunosuppressant for Systemic Lupus Erythematosus Players by Revenue
3.1.1 Global Top Immunosuppressant for Systemic Lupus Erythematosus Players by Revenue (2019-2024)
3.1.2 Global Immunosuppressant for Systemic Lupus Erythematosus Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Immunosuppressant for Systemic Lupus Erythematosus Revenue
3.4 Global Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Concentration Ratio
3.4.1 Global Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immunosuppressant for Systemic Lupus Erythematosus Revenue in 2023
3.5 Immunosuppressant for Systemic Lupus Erythematosus Key Players Head office and Area Served
3.6 Key Players Immunosuppressant for Systemic Lupus Erythematosus Product Solution and Service
3.7 Date of Enter into Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Immunosuppressant for Systemic Lupus Erythematosus Breakdown Data by Type
4.1 Global Immunosuppressant for Systemic Lupus Erythematosus Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Immunosuppressant for Systemic Lupus Erythematosus Forecasted 麻豆原创 Size by Type (2025-2030)
5 Immunosuppressant for Systemic Lupus Erythematosus Breakdown Data by Application
5.1 Global Immunosuppressant for Systemic Lupus Erythematosus Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Immunosuppressant for Systemic Lupus Erythematosus Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size (2019-2030)
6.2 North America Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Country (2019-2024)
6.4 North America Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size (2019-2030)
7.2 Europe Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Country (2019-2024)
7.4 Europe Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size (2019-2030)
9.2 Latin America Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Immunosuppressant for Systemic Lupus Erythematosus 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alcon
11.1.1 Alcon Company Detail
11.1.2 Alcon Business Overview
11.1.3 Alcon Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.1.4 Alcon Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.1.5 Alcon Recent Development
11.2 Alkem Laboratories
11.2.1 Alkem Laboratories Company Detail
11.2.2 Alkem Laboratories Business Overview
11.2.3 Alkem Laboratories Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.2.4 Alkem Laboratories Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.2.5 Alkem Laboratories Recent Development
11.3 Allergan
11.3.1 Allergan Company Detail
11.3.2 Allergan Business Overview
11.3.3 Allergan Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.3.4 Allergan Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.3.5 Allergan Recent Development
11.4 Amneal Pharmaceuticals
11.4.1 Amneal Pharmaceuticals Company Detail
11.4.2 Amneal Pharmaceuticals Business Overview
11.4.3 Amneal Pharmaceuticals Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.4.4 Amneal Pharmaceuticals Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.4.5 Amneal Pharmaceuticals Recent Development
11.5 Astellas Pharma
11.5.1 Astellas Pharma Company Detail
11.5.2 Astellas Pharma Business Overview
11.5.3 Astellas Pharma Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.5.4 Astellas Pharma Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.5.5 Astellas Pharma Recent Development
11.6 Baxter
11.6.1 Baxter Company Detail
11.6.2 Baxter Business Overview
11.6.3 Baxter Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.6.4 Baxter Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.6.5 Baxter Recent Development
11.7 Beijing Jialin Pharmaceutical
11.7.1 Beijing Jialin Pharmaceutical Company Detail
11.7.2 Beijing Jialin Pharmaceutical Business Overview
11.7.3 Beijing Jialin Pharmaceutical Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.7.4 Beijing Jialin Pharmaceutical Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.7.5 Beijing Jialin Pharmaceutical Recent Development
11.8 Genentech
11.8.1 Genentech Company Detail
11.8.2 Genentech Business Overview
11.8.3 Genentech Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.8.4 Genentech Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.8.5 Genentech Recent Development
11.9 Jubilant Cadista
11.9.1 Jubilant Cadista Company Detail
11.9.2 Jubilant Cadista Business Overview
11.9.3 Jubilant Cadista Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.9.4 Jubilant Cadista Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.9.5 Jubilant Cadista Recent Development
11.10 LGM Pharma
11.10.1 LGM Pharma Company Detail
11.10.2 LGM Pharma Business Overview
11.10.3 LGM Pharma Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.10.4 LGM Pharma Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.10.5 LGM Pharma Recent Development
11.11 LingNan Pharmaceutical
11.11.1 LingNan Pharmaceutical Company Detail
11.11.2 LingNan Pharmaceutical Business Overview
11.11.3 LingNan Pharmaceutical Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.11.4 LingNan Pharmaceutical Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.11.5 LingNan Pharmaceutical Recent Development
11.12 Merck
11.12.1 Merck Company Detail
11.12.2 Merck Business Overview
11.12.3 Merck Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.12.4 Merck Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.12.5 Merck Recent Development
11.13 Mimetogen Pharmaceuticals
11.13.1 Mimetogen Pharmaceuticals Company Detail
11.13.2 Mimetogen Pharmaceuticals Business Overview
11.13.3 Mimetogen Pharmaceuticals Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.13.4 Mimetogen Pharmaceuticals Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.13.5 Mimetogen Pharmaceuticals Recent Development
11.14 Mylan
11.14.1 Mylan Company Detail
11.14.2 Mylan Business Overview
11.14.3 Mylan Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.14.4 Mylan Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.14.5 Mylan Recent Development
11.15 Otsuka Pharmaceutical
11.15.1 Otsuka Pharmaceutical Company Detail
11.15.2 Otsuka Pharmaceutical Business Overview
11.15.3 Otsuka Pharmaceutical Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.15.4 Otsuka Pharmaceutical Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.15.5 Otsuka Pharmaceutical Recent Development
11.16 Par Pharmaceutical
11.16.1 Par Pharmaceutical Company Detail
11.16.2 Par Pharmaceutical Business Overview
11.16.3 Par Pharmaceutical Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.16.4 Par Pharmaceutical Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.16.5 Par Pharmaceutical Recent Development
11.17 Pfizer
11.17.1 Pfizer Company Detail
11.17.2 Pfizer Business Overview
11.17.3 Pfizer Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.17.4 Pfizer Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.17.5 Pfizer Recent Development
11.18 Powerdone
11.18.1 Powerdone Company Detail
11.18.2 Powerdone Business Overview
11.18.3 Powerdone Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.18.4 Powerdone Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.18.5 Powerdone Recent Development
11.19 Regenerx Biopharmaceuticals
11.19.1 Regenerx Biopharmaceuticals Company Detail
11.19.2 Regenerx Biopharmaceuticals Business Overview
11.19.3 Regenerx Biopharmaceuticals Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.19.4 Regenerx Biopharmaceuticals Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.19.5 Regenerx Biopharmaceuticals Recent Development
11.20 Roxane Laboratories
11.20.1 Roxane Laboratories Company Detail
11.20.2 Roxane Laboratories Business Overview
11.20.3 Roxane Laboratories Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.20.4 Roxane Laboratories Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.20.5 Roxane Laboratories Recent Development
11.21 Sandoz
11.21.1 Sandoz Company Detail
11.21.2 Sandoz Business Overview
11.21.3 Sandoz Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.21.4 Sandoz Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.21.5 Sandoz Recent Development
11.22 Sanofi
11.22.1 Sanofi Company Detail
11.22.2 Sanofi Business Overview
11.22.3 Sanofi Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.22.4 Sanofi Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.22.5 Sanofi Recent Development
11.23 Santen Pharmaceutical
11.23.1 Santen Pharmaceutical Company Detail
11.23.2 Santen Pharmaceutical Business Overview
11.23.3 Santen Pharmaceutical Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.23.4 Santen Pharmaceutical Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.23.5 Santen Pharmaceutical Recent Development
11.24 Takeda
11.24.1 Takeda Company Detail
11.24.2 Takeda Business Overview
11.24.3 Takeda Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.24.4 Takeda Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.24.5 Takeda Recent Development
11.25 Sine
11.25.1 Sine Company Detail
11.25.2 Sine Business Overview
11.25.3 Sine Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.25.4 Sine Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.25.5 Sine Recent Development
11.26 Strides Pharma
11.26.1 Strides Pharma Company Detail
11.26.2 Strides Pharma Business Overview
11.26.3 Strides Pharma Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.26.4 Strides Pharma Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.26.5 Strides Pharma Recent Development
11.27 Talon Therapeutics
11.27.1 Talon Therapeutics Company Detail
11.27.2 Talon Therapeutics Business Overview
11.27.3 Talon Therapeutics Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.27.4 Talon Therapeutics Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.27.5 Talon Therapeutics Recent Development
11.28 Teva
11.28.1 Teva Company Detail
11.28.2 Teva Business Overview
11.28.3 Teva Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.28.4 Teva Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.28.5 Teva Recent Development
11.29 United Biotech
11.29.1 United Biotech Company Detail
11.29.2 United Biotech Business Overview
11.29.3 United Biotech Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.29.4 United Biotech Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.29.5 United Biotech Recent Development
11.30 West Ward Pharmaceuticals
11.30.1 West Ward Pharmaceuticals Company Detail
11.30.2 West Ward Pharmaceuticals Business Overview
11.30.3 West Ward Pharmaceuticals Immunosuppressant for Systemic Lupus Erythematosus Introduction
11.30.4 West Ward Pharmaceuticals Revenue in Immunosuppressant for Systemic Lupus Erythematosus Business (2019-2024)
11.30.5 West Ward Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Alcon
Alkem Laboratories
Allergan
Amneal Pharmaceuticals
Astellas Pharma
Baxter
Beijing Jialin Pharmaceutical
Genentech
Jubilant Cadista
LGM Pharma
LingNan Pharmaceutical
Merck
Mimetogen Pharmaceuticals
Mylan
Otsuka Pharmaceutical
Par Pharmaceutical
Pfizer
Powerdone
Regenerx Biopharmaceuticals
Roxane Laboratories
Sandoz
Sanofi
Santen Pharmaceutical
Takeda
Sine
Strides Pharma
Talon Therapeutics
Teva
United Biotech
West Ward Pharmaceuticals
听
听
*If Applicable.
